

11. (New) The method of claim 10, wherein said nucleic acid sequence is inserted into a region essential for the replication of said viral vector.

12. (New) The method of claim 10, wherein said nucleic sequence encodes a polypeptide having thrombolytic properties.

13. (New) The method of claim 10, wherein said nucleic acid sequence encloses a polypeptide which is all or part of a dystrophin gene product.

14. (New) The method of claim 10 wherein said promoter is a promoter contained in the long terminal Repeat of a Rous Sarcoma Virus.

Bl Cont Sub-c 15. (New) A composition for treatment of muscular diseases comprising (i) a non replicative recombinant viral vector wherein said viral vector comprises a polynucleotide sequence under the control of a promoter recognized by polymerases of muscle cells and wherein said polypeptide is expressed in said muscle cells, associated with (ii) a pharmaceutically acceptable carrier.

16. (New) The composition of claim 15 wherein said muscular disease is a cardiac disease.

REMARKS


By way of the present preliminary amendment, Applicant has cancelled claim 1 and added claims 10-16. No new matter is added by this amendment. Claims 10-16 are pending in the instant application. Applicants respectfully submit that the claims are supported by the specification.

If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Respectfully submitted,

Merchant & Gould P.C.
3100 Norwest Center
90 South Seventh Street
Minneapolis, MN 55402
612/332-5300

Dated: Dec 6, 1999


Mark T. Skoog
Reg. No. 40,178
MTS:PSTslc